The post Ozempic’s Newest Miracle: Dramatically Cutting Dementia Risk appeared on BitcoinEthereumNews.com.

In brief A massive U.S. study found diabetics on semaglutide (Ozempic’s active ingredient) had up to 70% lower risk of Alzheimer’s-related dementia than those on other meds. Scientists believe Ozempic’s brain benefits may come from reducing inflammation and helping flush out toxic proteins linked to neurodegeneration. Experts urge caution: the findings are observational, not proof—clinical trials are still needed before prescribing Ozempic for brain health. A new study published Tuesday in the Journal of Alzheimer’s Disease tracked nearly 1.7 million Americans with Type 2 diabetes for three years, finding that people taking semaglutide—the active ingredient in the popular fat burning drugs Ozempic and Wegovy—had their risk of developing Alzheimer’s-related dementia cut by 40 to 70% compared to those on other diabetes medications. “We show that semaglutide was associated with a significantly reduced risk of overall ADRD (Alzheimer’s disease-related dementia) incidence with a hazard ratio ranging from 0.54 (0.49–0.59) compared with insulin, 0.67 (0.61–0.74) compared with metformin, to 0.80 (0.72–0.89) compared with older generation glucagon-like peptide-1 agonists (GLP-1RAs),” the study reads. “These findings provide evidence supporting protective effects of semaglutide on dementias in patients with T2D (Type 2 diabetes).” The numbers get more interesting when you dig deeper. Against vascular dementia—the second most common form after Alzheimer’s—semaglutide showed particularly strong protective effects. But it didn’t work for everything. Frontotemporal dementia and Lewy body dementia showed little change in the drug’s effects. This isn’t some happy coincidence. Scientists believe that semaglutide achieves this brain-protecting effect through multiple pathways. Beyond controlling blood sugar and promoting weight loss, the drug appears to reduce inflammation throughout the body, including the brain. Some preclinical studies suggest it might even help clear out the toxic proteins that gum up neurons in Alzheimer’s disease. “Additionally, GLP-1 receptor agonists (like semaglutide) have shown neuroprotective effects,” Manisha Parulekar from Hackensack…

---

Filed under: News - @ June 26, 2025 1:23 am